Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Search
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)
Hang Seng
17,575.52
(-0.34%)
Dow Jones
40,415.44
(0.32%)
Nikkei 225
39,707.92
(0.28%)
FTSE 100
8,198.78
(0.53%)
USD/AUD
0.6690
(-0.32%)
Bitcoin
67,675.89
(-1.09%)
Oil
79.95
(0.21%)
Gold
2,403.00
(0.35%)
Lithium
41.42
(1.37%)
Iron Ore
102.55
(-0.9%)

Argenica Therapeutics (ASX:$AGN) progresses phase 2 stroke clinical trial

Argenica Therapeutics (ASX:$AGN) Phase 2 stroke clinical trial update


Argenica Therapeutics Limited (ASX:AGN) has completed the manufacturing of the ARG-007 drug substance required for the Phase 2 clinical trial, with the finalised sterile drug product manufacturing to be completed by the end of Q4 CY2023. The company is on track to commence patient dosing in Q1 CY2024. Additionally, approvals for hospital clinical trial sites remain on track, with one hospital ready to commence patient dosing, and several others in the final stages of approval. Argenica has also established an independent Data Safety Monitoring Board (DSMB) for the Phase 2 trial.

Executive Commentary on Phase 2 Stroke Clinical Trial Progress


Proving the scale-up manufacturing of the clinical grade ARG-007 drug product is a significant milestone for the Company, and we are delighted manufacturing timelines remain on track. Further, we are pleased with the progress of research governance at each hospital, there is a lot of work going on behind the scenes in the Company to prepare for our upcoming Phase 2 trial. We look forward to keeping shareholders updated as further milestones are achieved.

Summary of Argenica Therapeutics Phase 2 Stroke Clinical Trial Update


Argenica Therapeutics (ASX:AGN) has made significant progress in the Phase 2 stroke clinical trial, with the completion of manufacturing of the ARG-007 drug substance and the establishment of hospital clinical trial sites. The company is on track to commence patient dosing in Q1 CY2024. The Phase 2 trial aims to provide data on the safety and preliminary efficacy of ARG-007 in acute ischaemic stroke patients, paving the way for a pivotal Phase 3 trial and potential partnering with pharmaceutical companies. Additionally, the trial is designed to generate preliminary data on the ability of ARG-007 to reduce brain tissue death following stroke and mechanical removal of brain clot. Argenica's ambitions include progressing to a pivotal Phase 3 trial and engaging with global pharmaceutical companies, positioning the company at the forefront of neuroprotective clinical validation.

Sourcehttps://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf

Share to Social
3 Comments
Inline Feedbacks
View all comments
Edward
Edward
7 months ago

Is this for real and do you think it will work?

Edward
Edward
7 months ago

Let us wait and see the outcome. Do you know when they will commence the trial?

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions